Does This Provide a Reason to Buy Albireo Pharma, Inc. (ALBO)? The Stock Has Formed Bullish Double Top

May 17, 2018 - By Jason Grubb

The chart of Albireo Pharma, Inc. (ALBO) shows a double top with $34.71 target or 7.00 % above today’s $32.44 share price. The 7 months chart pattern indicates low risk for the $387.40 million company. It was reported on May, 17 by Finviz.com. If the $34.71 price target is reached, the company will be worth $27.12 million more. Double tops are rare but powerful chart patterns.

The stock decreased 3.85% or $1.3 during the last trading session, reaching $32.44. About 50,151 shares traded. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 43.49% since May 17, 2017 and is uptrending. It has outperformed by 31.94% the S&P500.

More notable recent Albireo Pharma, Inc. (NASDAQ:ALBO) news were published by: Streetinsider.com which released: “Albireo Pharma (ALBO) Reports First Patient Enrollment in Phase 3 PFIC Trial of A4250” on May 16, 2018, also Benzinga.com with their article: “Earnings Scheduled For May 17, 2018” published on May 17, 2018, Streetinsider.com published: “Jefferies Starts Albireo Pharma (ALBO) at Buy” on April 20, 2018. More interesting news about Albireo Pharma, Inc. (NASDAQ:ALBO) were released by: Nasdaq.com and their article: “Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting” published on April 19, 2018 as well as Nasdaq.com‘s news article titled: “Albireo to Host First Quarter 2018 Business Update Conference Call and Webcast on May 17, 2018” with publication date: May 09, 2018.

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders in the United States. The company has market cap of $387.40 million. The Company’s lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. It currently has negative earnings. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption.

Albireo Pharma, Inc. (NASDAQ:ALBO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.